Cure Brain Cancer’s Early Career Fellowships aim to support bright young researchers to develop their career in brain cancer research. Cure Brain Cancer believes that it is important to build capacity in innovative brain cancer research and development to achieve our mission of improving survival for people living with brain cancer. It is expected that Fellows undertake a significant piece of publishable work during their tenure that will lead to a more permanent position within the brain cancer research field.
The Cure Brain Cancer Early Career Fellowship will offer
grants in aid of up to $70,000 for salary per year for up to three years. The
level of funding will depend on the academic level of the applicant. We will
also offer an additional $15k for consumables with up to $5k of that amount
available for travel and conferences per year.
University of Queensland, Institute for Molecular Bioscience, QLD (2017)
The therapeutic targeting of cell cycle regulators and mechanisms of resistance to cell cycle therapy in Medulloblastoma
Medulloblastoma is a leading cause of cancer-related mortality and morbidity in children. Few effective therapies are available for patients with high-risk disease or tumours that recur following standard-of-care therapy and thus, these patients have a poor prognosis. Based on this, Dr Genovesi has focused on identifying novel Medulloblastoma targeted therapies for Medulloblastoma. Using a functional genomics and bioinformatics approach in a Medulloblastoma biological model, gene networks dysregulated in all Medulloblastoma subgroups have been identified. A druggable genome analysis of these networks defined potential new therapeutics, validating CDK4/6 inhibition as a possible therapeutic strategy for multiple subgroups of Medulloblastoma.
The Walter and Eliza Hall Institute of Medical Research, VIC (2017)
Designing immune killer cells for adults and children with brain cancer
T cells are white blood cells which can recognise and kill tumour target cells. However, tumours often outsmart the T cells so they can't kill them anymore. Dr Cross aims to re-arm these T cells with new genetically engineered weapons to kill highly fatal brain cancers in both children and adults. These weapons are called Chimeric Antigen Receptors (CAR) and are a form of adoptive cell immunotherapy. In this project he will generate and validate CARs to treat High Grade Glioma (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG), with the aim to rapidly translate any findings into clinical trials.
for all the latest research, events and fundraising news